Search Within

Michael Andrew Postow

Formats
  1. Journal Article (191)
  2. Meeting Abstract (137)
  3. Editorial (9)
  4. Review (9)
  5. Book Section (4)
  6. Guidelines (4)
  7. Research Letter (4)
  8. Miscellaneous (2)
  9. Book Whole (1)
  10. Correspondence (1)
Groups
  1. Department of Medicine (362)
  2. Melanoma Disease Management Team (362)
  3. Melanoma and Immunotherapeutics Service (362)
  4. Solid Tumor Oncology Division (362)
  5. GSK Faculty (178)
  6. Hematologic Malignancies, Division of (103)

More Groups

People
  1. Jedd Wolchok (158)
  2. Margaret Callahan (95)
  3. Katherine Panageas (64)
  4. Alexander Shoushtari (63)
  5. Paul Chapman (54)
  6. Parisa Momtaz (36)

More People

Years
  1. 2025 (16)
  2. 2024 (19)
  3. 2023 (23)
  4. 2022 (23)
  5. 2021 (27)
  6. 2020 (30)

More Years

Publications
  1. Journal of Clinical Oncology (90)
  2. Journal for ImmunoTherapy of Cancer (34)
  3. Clinical Cancer Research (16)
  4. Annals of Oncology (13)
  5. International Journal of Radiation Oncology, Biology, Physics (12)
  6. The Oncologist (12)

More Publications

Publishers
  1. American Society of Clinical Oncology (92)
  2. Biomed Central Ltd (43)
  3. Oxford University Press (32)
  4. Elsevier Inc. (31)
  5. American Association for Cancer Research (24)
  6. Wiley Blackwell (21)

More Publishers

Results (362)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase 1 study of NY-ESO-1 vaccine + ipilimumab (ipi) in patients with unresectable or metastatic melanoma
    Meeting Abstract

    Slingluff, C.; Zarour, H.; Postow, M.; Friedlander, P.; Devoe, C.; Mauldin, I.; Smith, K.; Macri, M.
    Journal for ImmunoTherapy of Cancer (2019)

    Fulltext@MSK | Save
  • Responders to anti-PD1 therapy: Long-term outcomes and responses to retreatment in melanoma (mel)
    Meeting Abstract

    Warner, A. B.; Palmer, J. S.; Shoushtari, A. N.; Goldman, D. A.; Panageas, K.; Callahan, M. K.; Wolchok, J. D.; Postow, M. A.; Chapman, P. B.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Efficacy and safety of the combination of nivolumab (NIVO) plus ipilimumab (IPI) in patients with symptomatic melanoma brain metastases (CheckMate 204)
    Meeting Abstract

    Tawbi, H. A. H.; Forsyth, P. A. J.; Hodi, F. S.; Lao, C. D.; Moschos, S. J.; Hamid, O.; Atkins, M. B.; Lewis, K. D.; Thomas, R. P.; Glaspy, J. A.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Therapeutic implications of a novel driver classification system for cutaneous and unknown primary melanomas
    Meeting Abstract

    Shoushtari, A. N.; Sanchez-Vega, F.; Kantheti, H.; Callahan, M. K.; Postow, M. A.; Barker, C. A.; Chatila, W. K.; Jonsson, P.; Ariyan, C. E.; Brady, M. S.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Long-term symptom burden and quality of life in metastatic melanoma patients treated with checkpoint inhibitors
    Meeting Abstract

    Mamoor, M.; Lavery, J. A.; Sidlow, R.; Rogak, L. J.; Thom, B.; Khan, N.; Baxi, S. S.; Wolchok, J. D.; Postow, M. A.; Korenstein, D.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • A phase II, open label, randomized controlled trial of nivolumab plus ipilimumab with stereotactic radiotherapy versus ipilimumab plus nivolumab alone in patients with melanoma brain metastases (ABC-X Trial)
    Meeting Abstract

    Gonzalez, M.; Hong, A. M.; Carlino, M. S.; Atkinson, V.; Wang, W.; Lo, S.; Brown, M. P.; Foote, M. C.; Pinkham, M. B.; Le, H.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Long-term follow-up of CA209-004: A phase I dose-escalation study of combined nivolumab (NIVO) and ipilimumab (IPI) in patients with advanced melanoma
    Meeting Abstract

    Atkins, M. B.; Kirkwood, J. M.; Wolchok, J. D.; Callahan, M. K.; Kluger, H. M.; Postow, M. A.; Segal, N. H.; Lesokhin, A. M.; Balogh, A.; Re, S.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Indications and toxicities of immune checkpoint inhibitor combinations
    Book Section

    Spain, L.; Postow, M. A.; Larkin, J.; Weber, J.
    In Ernstoff, M. S.; Puzanov, I.; Robert, C.; Diab, A.; Hersey, P. (Eds.) SITC's Guide to Managing Immunotherapy Toxicity (2019)

    Fulltext@MSK | Save
  • Treatment outcomes of immune-related cutaneous adverse events
    Journal Article

    Phillips, G. S.; Wu, J.; Hellmann, M. D.; Postow, M. A.; Rizvi, N. A.; Freites-Martinez, A.; Chan, D.; Dusza, S.; Motzer, R. J.; Rosenberg, J. E.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Neoadjuvant systemic therapy in melanoma: Recommendations of the International Neoadjuvant Melanoma Consortium
    Guidelines

    Amaria, R. N.; Menzies, A. M.; Burton, E. M.; Scolyer, R. A.; Tetzlaff, M. T.; Antdbacka, R.; Ariyan, C.; Bassett, R.; Carter, B.; Daud, A.; more...
    Lancet Oncology (2019)

    Fulltext@MSK | Save